Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Brauchli

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Contemporary Clinical Trials|May 28, 2009
A novel diagram and complement to the CONSORT chart for presenting multimodal clinical trialsJan C Schuller, Michael Mayer, Doris Lanz, et al.
Surgical Oncology|June 6, 2024
Is surgical quality more important than radicality? Long-term outcomes of stage I-III colon cancer (SAKK 40/00)Christoph A Maurer, Daniel Dietrich, Martin K Schilling, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2009
Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluationKonstantin J Dedes, Klazien Matter-Walstra, Matthias Schwenkglenks, et al.
Oncology|November 13, 2004
Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trialCatrina Uhlmann, Pierluigi Ballabeni, Natalie Rijken, et al.
Cancer Treatment Reviews|July 1, 2016
Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?Piera Gargiulo, Chiara Della Pepa, Simona Berardi, et al.
Therapeutic Advances in Medical Oncology|January 15, 2019
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scoresPiera Gargiulo, Daniel Dietrich, Richard Herrmann, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2018
Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trialSabine Tejpar, Pu Yan, Hubert Piessevaux, et al.
BMC Medical Informatics and Decision Making|August 27, 2013
The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patientsKerri M Clough-Gorr, Lea Noti, Peter Brauchli, et al.
Annals of Surgery|July 26, 2017
Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal CancerThomas Steffen, Daniel Dietrich, Annelies Schnider, et al.
Leukemia & Lymphoma|March 12, 2010
Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02)Nicolas Leupin, Jan C Schuller, Max Solenthaler, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Contemporary Clinical Trials|May 28, 2009
A novel diagram and complement to the CONSORT chart for presenting multimodal clinical trialsJan C Schuller, Michael Mayer, Doris Lanz, et al.
Surgical Oncology|June 6, 2024
Is surgical quality more important than radicality? Long-term outcomes of stage I-III colon cancer (SAKK 40/00)Christoph A Maurer, Daniel Dietrich, Martin K Schilling, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2009
Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluationKonstantin J Dedes, Klazien Matter-Walstra, Matthias Schwenkglenks, et al.
Oncology|November 13, 2004
Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trialCatrina Uhlmann, Pierluigi Ballabeni, Natalie Rijken, et al.
Cancer Treatment Reviews|July 1, 2016
Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?Piera Gargiulo, Chiara Della Pepa, Simona Berardi, et al.
Therapeutic Advances in Medical Oncology|January 15, 2019
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scoresPiera Gargiulo, Daniel Dietrich, Richard Herrmann, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2018
Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trialSabine Tejpar, Pu Yan, Hubert Piessevaux, et al.
BMC Medical Informatics and Decision Making|August 27, 2013
The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patientsKerri M Clough-Gorr, Lea Noti, Peter Brauchli, et al.
Annals of Surgery|July 26, 2017
Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal CancerThomas Steffen, Daniel Dietrich, Annelies Schnider, et al.
Leukemia & Lymphoma|March 12, 2010
Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02)Nicolas Leupin, Jan C Schuller, Max Solenthaler, et al.
Pageof 3